Investing.com - U.S. stocks edged lower on Tuesday, as investors assessed a weaker-than-anticipated reading on consumer confidence and took some caution ahead of crucial quarterly ...
Danish pharma major Novo Nordisk has announced the appointment of Sebnem Avsar Tuna as the new general manager (GM) of its UK ...
12h
Investor's Business Daily on MSNIBD 50's No. 2, Hims & Hers, Crashes 15% Despite Upbeat EarningsCompounding pharmacy and IBD 50 newcomer Hims & Hers Health reported bullish earnings and sales growth late Monday. But Hims ...
Investors are scrambling to adjust, after the telehealth specialist Hims & Hers said it would stop selling an alternative to ...
Meanwhile, Hims & Hers (NYSE: HIMS) warned that it may stop selling legal copies of a popular weight-loss drug made by Denmark's Novo Nordisk (NYSE: NVO ), sending shares in the U.S. telehealth firm ...
Weight-loss drugs aren’t just slimming waists; they create a $100 billion market opportunity. With plenty up for grabs, ...
Investing.com - Hims&Hers (NYSE:HIMS) said on Monday that it may stop selling legal copies of a popular weight-loss drug made by Denmark's Novo Nordisk (NYSE:NVO), sending shares in the U.S.
(Reuters) -Eli Lilly said on Tuesday it cut the price for vials of its weight-loss drug Zepbound by $50 or more and expanded ...
Elsewhere, gold prices ticked lower, but remained close to recent peaks as safe-haven demand was partly underpinned by ...
Investing.com - Hims & Hers said on Monday that it may stop selling legal copies of a popular weight-loss drug made by Denmark's Novo Nordisk (NYSE: NVO), sending shares in the U.
One is that Ireland has an unsustainable reliance on intellectual capital we do not own or create. Much of our economy is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results